News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AB Science (AB.PA) Announces That FDA Authorization (IND) Has Been Granted for the Initiation of Its Phase 3 Study in Severe Asthma. Patient Recruitment Commences in the US


9/14/2011 10:15:00 AM

PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB)(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today that it has obtained IND status (Investigation New Drug – authorization to administer an investigational drug to humans) from the US Food and Drug Administration (FDA) and can now commence its phase 3 study of masitinib in severe persistent asthma in the US. This study had previously received European authorization and has therefore already commenced patient recruitment from European sites earlier this year.

Read at BioSpace.com

comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES